Crinetics Pharmaceuticals (CRNX) Receivables - Other (2018 - 2026)

Crinetics Pharmaceuticals' Receivables - Other history runs 9 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 23.97% year-over-year to $9.0 million in Q1 2026; TTM through Mar 2026 was $9.0 million, a 23.97% increase from a year earlier, with the FY2025 full-year figure at $7.8 million, down 6.64% from the prior year.
• Receivables - Other climbed to $9.0 million in Q1 2026 per CRNX's latest filing, from $7.8 million in the prior quarter.
• Across five years, Receivables - Other topped out at $9.0 million in Q1 2026 and bottomed at $90000.0 in Q4 2023.
• The 5-year median for Receivables - Other is $2.6 million (2023), against an average of $3.6 million.
• Across the five-year window, Receivables - Other tumbled 93.35% in 2023 and surged 9133.33% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $1.4 million in 2022, then tumbled by 93.35% to $90000.0 in 2023, then jumped by 9133.33% to $8.3 million in 2024, then retreated by 6.64% to $7.8 million in 2025, then advanced by 15.46% to $9.0 million in 2026.
• Per Business Quant, the three latest CRNX Receivables - Other figures stand at $9.0 million (Q1 2026), $7.8 million (Q4 2025), and $6.3 million (Q3 2025).